Because the encapsulation of highly expressed CD47 biomimetic membrane, meTGCT exhibits superior immune escape ability as well as homologous targeting ability, which can be preferentially targeted to tumor sites and effectively enhanced tumor cell uptake. The gene discussed is CD47; the disease is neoplasm.